ALMS Alumis Inc.

NASDAQ
$25.31

Alumis Inc. (ALMS) is expected to report earnings on November 12, 2026, after the market close. The consensus earnings estimate is a loss of $0.69 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +9.1% since its last earnings release on August 13, 2026.

Alumis Missed Consensus Estimates
Thursday, August 13, 2026 · 4:01 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 12
Thursday · 4:05 PM ET
Earnings Whisper
-
vs ($0.69)
Rev est $4M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $25.31

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Alumis Inc.

Alumis Inc. is a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases. The company's product candidate includes ESK-001. Alumis Inc. is based in SOUTH SAN FRANCISCO, Calif.

Sector

Healthcare

Industry

Biotechnology